JP2009532326A5 - - Google Patents

Download PDF

Info

Publication number
JP2009532326A5
JP2009532326A5 JP2008554385A JP2008554385A JP2009532326A5 JP 2009532326 A5 JP2009532326 A5 JP 2009532326A5 JP 2008554385 A JP2008554385 A JP 2008554385A JP 2008554385 A JP2008554385 A JP 2008554385A JP 2009532326 A5 JP2009532326 A5 JP 2009532326A5
Authority
JP
Japan
Prior art keywords
zinc finger
finger protein
nucleic acid
acid encoding
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008554385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532326A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/003538 external-priority patent/WO2007092609A2/en
Publication of JP2009532326A publication Critical patent/JP2009532326A/ja
Publication of JP2009532326A5 publication Critical patent/JP2009532326A5/ja
Pending legal-status Critical Current

Links

JP2008554385A 2006-02-09 2007-02-09 ジンクフィンガータンパク質により末梢動脈疾患を処置するための方法 Pending JP2009532326A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77241706P 2006-02-09 2006-02-09
US80323406P 2006-05-25 2006-05-25
PCT/US2007/003538 WO2007092609A2 (en) 2006-02-09 2007-02-09 Method for treating peripheral arterial disease with zinc finger proteins

Publications (2)

Publication Number Publication Date
JP2009532326A JP2009532326A (ja) 2009-09-10
JP2009532326A5 true JP2009532326A5 (enExample) 2010-03-25

Family

ID=38345833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554385A Pending JP2009532326A (ja) 2006-02-09 2007-02-09 ジンクフィンガータンパク質により末梢動脈疾患を処置するための方法

Country Status (6)

Country Link
US (1) US20090305977A1 (enExample)
EP (1) EP1993586A4 (enExample)
JP (1) JP2009532326A (enExample)
AU (1) AU2007212260A1 (enExample)
CA (1) CA2641198A1 (enExample)
WO (1) WO2007092609A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6140466A (en) * 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
AU767662B2 (en) * 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7223740B2 (en) * 2001-05-23 2007-05-29 Fornix Biosciences N.V. Vectors for enhanced expression of VEGF for atrial disease treatment
BRPI0410844A (pt) * 2003-06-05 2006-06-27 Centelion fator de crescimento de fibroblasto de codificação de plasmìdeo para o tratamento de defeitos angiogênicos associados com hipercolesterolemia ou diabetes
EP1631676A4 (en) * 2003-06-10 2006-12-20 Toolgen Inc TRANSDUCIBLE DNA BINDING PROTEINS
ES2315859T3 (es) * 2004-04-08 2009-04-01 Sangamo Biosciences, Inc. Metodos y composiciones para tratar afecciones neuropaticas y neurodegenerativas.

Similar Documents

Publication Publication Date Title
Torres-Espín et al. Eliciting inflammation enables successful rehabilitative training in chronic spinal cord injury
Trakhtenberg et al. Zinc chelation and Klf9 knockdown cooperatively promote axon regeneration after optic nerve injury
Yehya et al. Angiogenesis: managing the culprits behind tumorigenesis and metastasis
Shen et al. Dose‐dependent functional benefit of human cardiosphere transplantation in mice with acute myocardial infarction
JP2020040969A5 (enExample)
ES2653615T3 (es) Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos
JP2014169326A5 (enExample)
Rubanyi Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors
JP2012067116A5 (enExample)
JP2012041342A5 (enExample)
JP2010526153A5 (enExample)
JP2010500370A5 (enExample)
JP2020510039A5 (enExample)
JP2009532326A5 (enExample)
RU2010145048A (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
JP2016501528A5 (enExample)
ES2717661T3 (es) Terapia de combinación para el tratamiento de las enfermedades autoinmunes
RU2016149316A (ru) Лечение ревматоидного артрита
Lu et al. Hiv/aids curable study: new forms of therapeutic trinity
Macagno et al. New treatment directions for IPF: current status of ongoing and upcoming clinical trials
RU2017126212A (ru) Композиция
Boyle et al. Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man
CN101920015A (zh) 一种治疗癌症的药物组合物
Ma et al. Tongxinluo mitigates atherogenesis by regulating angiogenic factors and inhibiting vasa vasorum neovascularization in apolipoprotein E-deficient mice
Marcu Improving Therapeutic Ratio in Head and Neck Cancer with Adjuvant and Cisplatin‐Based Treatments